7月10日，诺诚健华盘中上涨5.07%，报14.09港元，成交额7312.06万港元。
消息面上，港股创新药概念股盘中集体拉升，荣昌生物、诺诚健华涨超5%，药明康德、药明生物、亚盛医药涨超4%，恒瑞医药涨超3%，板块资金回流明显。公司层面，诺诚健华此前宣布自主研发的靶向CDH17新型ADC创新药ICP-B208完成首例患者给药，正式进入临床阶段，全球尚无CDH17靶向ADC新药上市，该管线差异化优势突出。此外，公司核心产品奥布替尼治疗ITP的新药上市申请已获CDE受理，坦昔妥单抗联合疗法全球III期研究数据于EHA年会重磅发布，多管线催化叠加板块联动共同推动股价走强。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.